Biotech Values

[krenjp]

"the average change from baseline for the six non-study eyes would surely have been greater than 0.5 lines, which is the amount reported in slide #13 from GENR's "Corporate Overview" slides."

I don't necessarily disagree with you that the value would seemingly be bigger had two patients reached 5.6 lines positive. But the value reported in slide 13 is not the average but the mean; if the distribution is not symetrical the value of the mean will be different than the average. So it is still possible to have two patients with +5.6 and a third or fourth patient at 0.5. Although this is quite a wide margin and difficult to believe but again, this is a small n.

Anyway, I wonder what you make of slide 19 on the mean VA change with Squalamine +1.1 versus Visudyne -1.1? This seems very positive, but I do not have a basis of comparison with Visudyne to say. Apparently the Visudyne data comes from their phase 3.